-
Endologix Announces Favorable Markman Ruling in Cook Patent Litigation
Wednesday, August 17, 2011 - 8:15am | 164Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that Judge Tanya Walton Pratt of the United States District Court for the Southern District of Indiana in Indianapolis has issued a Markman ruling in the ongoing patent...
-
Atrion Announces 200,000 Share Buyback
Tuesday, August 16, 2011 - 8:41pm | 149Atrion (NASDAQ: ATRI) announced that its Board of Directors updated the Company's stock repurchase program, which was adopted in April 2000 and authorized the repurchase of up to 200,000 shares of the Company's common stock. A total of 58,105 shares remained eligible for repurchase under the April...
-
Immucor Announces End of "Go-Shop" Period
Tuesday, August 16, 2011 - 7:34am | 111Immucor, Inc. (Nasdaq: BLUD) today announced the expiration of the "go-shop" period pursuant to the terms of the previously announced merger agreement, dated as of July 2, 2011, which contemplates the acquisition of the Company by an affiliate of TPG Capital, L.P. The "go-shop" period expired at...
-
Options Brief: Immucor
Wednesday, August 10, 2011 - 10:39am | 84Shares of Immucor (NASDAQ: BLUD) are lower on the session by 0.19%, trading at $26.60. Overall call volume is now running at 4.08x the daily average, with 2% of all calls traded being purchases on the offer. 1,216 contracts have traded on the session so far. Immucor, Inc. develops, manufactures...
-
Wednesday's NASDAQ Top Winners: Energy Focus, STARR Surgical, Silicon Image, Global Traffic Network
Thursday, August 4, 2011 - 9:43am | 532investors, reports on top percentage gainers on the NASDAQ for Aug. 03, 2011. In Wednesday's session, Energy Focus was the notable gainer, as the stock soared 45.24%. Energy Focus, Inc. (NASDAQ: EFOI) was the biggest gaineron Nasdaq and soared 0.190 (45.24%) to $0.610. U.S. Rep. Steven C....
-
Immucor and IVD Acquisition Corporation Announce German Antitrust and Merger Control Clearance
Thursday, August 4, 2011 - 7:01am | 270Immucor, Inc. (Nasdaq: BLUD) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P., today announced that Germany's Federal Cartel Office has granted clearance in connection with IVD Acquisition Corporation's previously announced transaction to acquire the Company. As announced on...
-
Barrington Upgrades Haemonetics To Outperform, $70 PT
Wednesday, August 3, 2011 - 8:09am | 25Barrington Research has upgraded Haemonetics (NYSE: HAE) from Perform to Outperform and has established a $70 price target.
-
Duncan Williams Raises PT On Vascular Solutions To $17
Wednesday, August 3, 2011 - 8:03am | 27Duncan Williams has raised the price target on Vascular Solutions (NASDAQ: VASC) from $15 to $17 and maintains its Buy rating.
-
Immucor and IVD Acquisition Corporation Announce Expiration of HSR Waiting Period
Wednesday, August 3, 2011 - 7:06am | 84Immucor, Inc. (Nasdaq: BLUD) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P., today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to IVD Acquisition Corporation's previously announced tender...
-
Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows
Wednesday, August 3, 2011 - 12:05am | 5002Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to...
-
Morgan Stanley Takes a Look at Haemonetics
Tuesday, August 2, 2011 - 8:00am | 112Morgan Stanley has published a report on Haemonetics (NYSE: HAE). In the report, Morgan Stanley wrote, "Hospital sales are unlikely to show the reacceleration management was hoping for as the OrthoPAT recall cuts into growth and pulls sales force focus away from blood management. The company was...
-
UPDATE: Morgan Keegan Lowers PT on Haemonetics to $65
Tuesday, August 2, 2011 - 7:42am | 68Morgan Keegan is out with its report today on Haemonetics (NYSE: HAE), lowering its PT from $76 to $65. In its report, Morgan Keegan writes, "Although the decline in the stock appears overdone, with double-digit EPS growth not likely until the fiscal 4Q, we maintain our Market Perform rating. Our...
-
Morgan Keegan Lowers PT on Haemonetics To $65
Tuesday, August 2, 2011 - 6:12am | 28Morgan Keegan has lowered the price target on Haemonetics Corporation (NYSE: HAE) from $76 to $65 and maintains its Market Perform rating.
-
Duncan-Williams Previews 2Q Earnings for Vascular Solutions
Friday, July 29, 2011 - 9:25am | 103Duncan-Williams has published a research report on Vascular Solutions (NASDAQ: VASC) previewing earnings for the second quarter. In the report, Duncan-Williams wrote, "Our Q2:11 Catheters revenue estimate is $13.5 million. This represents approximately 31% growth compared to the same period last...
-
UPDATE: Benchmark Upgrades RTI Biologics from Hold to BUY
Friday, July 29, 2011 - 7:22am | 154Benchmark has published a report on RTI Biologics (NASDAQ: RTIX) upgrading the company from Hold to Buy. In the report, Benchmark wrote, "We are upgrading RTIX shares to Buy from Hold based on stronger then anticipated earnings and our view that Spine risks are abating. RTI's performance is...